IP Library Patent Application 11517582
Patent Application
App. No. 11/517,582

Prodrugs of T3 and T4 with enhanced bioavailability

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/517,582
Abstract

The invention relates to compositions of amino acid and peptide conjugates comprising T3 and/or T4. The T3 or T4 is covalently attached to at least one amino acid via the N-terminus, the C-terminus, a side chain of the peptide carrier, and/or interspersed within the peptide chain. Also discussed are methods for protecting and administering active agents and methods for treating thyroid disorders.

Claims (35)

1 . A composition comprising at least one peptidic-iodothyronine or salt thereof and at least one non-peptidic iodothyronine or salt thereof.

2 . The composition of claim 1 comprising Gly-T3 or salt thereof and T4 or salt thereof.

3 . The composition of claim 1 comprising Gly-T4 or salt thereof and T3 or salt thereof.

4 . A composition comprising Gly-T3 or salt thereof and Gly-T4 or salt thereof.

5 . A method of treating a thyroid disorder comprising orally administering to a human patient an iodothyronine prodrug or salt thereof wherein said prodrug comprises a single iodothyronine covalently bound through to the C-terminus of peptide carrier wherein the carrier peptide is fewer than 5 amino acid.

6 . The method of claim 5 , wherein said iodothyronine is T3.

7 . The method of claim 5 , wherein said iodothyronine is T4.

8 . The method of claim 6 , wherein said carrier peptide is a single amino acid.

9 . The method of claim 6 , wherein said carrier peptide is Gly, Lys, Glu, Ile, Tyr, Val, Ala-Ala, Pro-Pro, Glu-Glu or Phe-Phe.

10 . The method of claim 8 , wherein said prodrug is in salt form.

11 . The method of claim 8 , wherein said salt form is a HCl, acetate, sulfate, mesylate, citrate, phosphate, or tartrate salt.

12 . The method of claim 8 , wherein said salt form is an HCl salt.

13 . The method of claim 8 , wherein said prodrug is Gly-T3 or a salt thereof.

14 . The method of claim 8 or 13 , wherein said condition is hypothyroidism.

15 . The method of claim 8 or 13 , wherein said condition is depression.

16 . Gly-T3.

17 . Ile-T3.

18 . Tyr-T3.

19 . Ala-Ala-T3.

20 . Val-T3.

21 . Pro-Pro-T3.

22 . Phe-Phe-T3.

23 . Gly-T4.

24 . Ile-T4.

25 . Tyr-T4.

26 . Ala-Ala-T4.

27 . Val-T4.

28 . Pro-Pro-T4.

29 . Phe-Phe-T4.

30 . T4-Glu.

31 . T4-Glu-Glu.

32 . T4-Lys.

33 . Glu-T4.

34 . Glu-Glu-T4.

35 . Lys-T4.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2009
From: PICCARIELLO, THOMAS
To: SHIRE LLC
Reel/Frame 022156/0171 →
MERGER Recorded Nov 1, 2007
From: NEW RIVER PHARMACEUTICALS INC.
To: SHIRE LLC
Reel/Frame 020054/0484 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 3, 2007
From: MONCRIEF, JAMES SCOTT; MICKLE, TRAVIS; OLON, LAWRENCE
To: NEW RIVER PHARMACEUTICALS INC.
Reel/Frame 018747/0901 →